Movano

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Leabman in January 2018 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Movano Health reports revenue growth but faces operating loss in Q1 2024

Movano Health's Q1 2024 performance showed revenue from Evie Ring shipments but an operating loss, mitigated by a $24 million private placement. The company aims to optimize operations, secure FDA clearance, and expand partnerships to drive growth and profitability.

Movano Health advances FDA-cleared products, eyes clinical trials for growth

Movano Health's Q2 2024 earnings call highlighted progress, challenges, and opportunities in the health monitoring technology sector. With a focus on product development, marketing strategies, and capital management, Movano aims to drive growth and innovation in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif. , Nov. 7, 2024 /PRNewswire/ -- Movano Health Inc. (Nasdaq: MOVE) announced today that it has tested its newly developed blood pressure wrist wearable as part of its November 5 th and 6th hypoxia clinical trial that took place at the University of California, San Francisco.

Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device

Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif. , Nov. 6, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report third quarter 2024 financial and operating results on Thursday November 14, 2024, after the market close.

Movano Health to Report Third Quarter 2024 Financial Results on Thursday November 14, 2024

Company Continues to Work with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif. , Nov. 4, 2024 /PRNewswire/ -- Movano Health  (Nasdaq:  MOVE ) (the "Company") provided an update on an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholder approved reverse stock split.

Movano Health Provides Update on Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split

Company remains optimistic on the potential for this pioneering healthcare solution PLEASANTON, Calif. , Nov. 4, 2024 /PRNewswire/ -- Movano Health  (NASDAQ:  MOVE ) announced today that it has submitted a complete response package to the FDA as part of the final phase of the Company's 510(k) application review of the EvieMED Ring.

Movano Health Submits Response to FDA as Part of Final Review Phase for EvieMED

Company Communicating with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif. , Oct. 31, 2024 /PRNewswire/ --  Movano Health  (Nasdaq:  MOVE ) (the "Company") announced today that it has opened an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholder approved reverse stock split.

Movano Health Opens Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split

Collaboration Will Expand Awareness of Movano's Female First Wearable to D'Amelio's 12 Million Social Media Followers PLEASANTON, Calif. , Oct. 30, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced its first brand partnership with digital creator, wife, mom and entrepreneur Heidi D'Amelio.

Evie Ring Announces Brand Partnership with Lifestyle Content Creator Heidi D'Amelio

Shares Expected to Begin Trading on Split-Adjusted Basis on October 29, 2024 PLEASANTON, Calif. , Oct. 25, 2024 /PRNewswire/ --  Movano Health  (Nasdaq: MOVE) announced today that it will implement a 1-for-15 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m.

Movano Health Announces Reverse Stock Split

A successful response to requests for additional information would bring the Company one step closer to introducing this pioneering healthcare product to the market PLEASANTON, Calif. , Oct. 24, 2024 /PRNewswire/ -- Movano Health  (Nasdaq: MOVE) announced today that it plans to submit updated responses next week to all clarifying questions that it recently received from the FDA as part of the final phase of the Company's 510(k) application review.

Movano Health Plans Response Submission to FDA Next Week as Part of EvieMED Final Review Phase

The Company continues to work closely with the FDA to bring this pioneering healthcare product to market PLEASANTON, Calif. , Oct. 10, 2024 /PRNewswire/ -- Movano Health  (Nasdaq: MOVE) announced today that the Company recently received additional clarifying questions from the FDA related to medical aspects of the EvieMED Ring, as part of the final phase of the Company's 510(k) application review process.

Movano Health Provides Update on FDA Review of EvieMED Ring

Orders Reopen with Enhancements to AI Powered Health Insights, Sleep and Heart Rate Measurements and More PLEASANTON, Calif. , Sept. 17, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the immediate availability of its Evie Ring , the first smart ring designed specifically for women.

Evie, Movano Health's Smart Ring for Women, is Back In Stock with Key Upgrades

Following the positive outcome of a recent agency meeting, the Company will continue to work closely with the FDA to bring this pioneering healthcare product to market PLEASANTON, Calif. , Sept. 3, 2024 /PRNewswire/ --  Movano Health  (Nasdaq: MOVE) announced today that a productive in-person meeting with the FDA on August 15, 2024, resulted in a positive outcome regarding the EvieMED Ring's wellness features and metrics.

Movano Health Advances to Final Phase of FDA Review Process for EvieMED Ring

Movano Inc. (NASDAQ:MOVE ) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants Jay Cogan - CFO John Mastrototaro - CEO Tyla Bucher - Chief Marketing Officer Michael Leabman - Founder and Chief Technology Officer Michael Soule - Chief Commercial Officer Conference Call Participants Bruce Jackson - Benchmark Company Operator Greetings and welcome to Movano Health Q2 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Movano Inc. (MOVE) Q2 2024 Earnings Call Transcript

Prepares for September 17, 2024, Evie Ring back in stock date Announces brand partnership with digital creator Heidi D'Amelio Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. , Aug. 14, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update.

Movano Health Reports Q2 2024 Financial Results and Provides Business Update

Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif. , Aug. 5, 2024 /PRNewswire/ --  Movano Health  (Nasdaq:  MOVE ) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging.

Movano Health Provides Progress Update on EvieMED Regulatory Filing

Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif. , Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report second quarter 2024 financial and operating results on Wednesday, August 14, 2024, after the market close.

Movano Health to Report Second Quarter 2024 Financial Results on Wednesday August 14, 2024

Allele Capitals' Matt Hughes will moderate future forward panel on enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif. , June 28, 2024 /PRNewswire/ -- Movano Health  (Nasdaq: MOVE) announced the addition of two expert participants to its B2B: The Next Wearables Boom Virtual Event to be held on July 11 – Dr. Fatima Rodriguez and Matt Hughes.

Movano Health Announces Dr. Fatima Rodriguez Joining July 11 Virtual Event

Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health  (Nasdaq:  MOVE ) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing.

Movano Health Applies Advanced AI through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion

Pioneering partnership advances innovative health monitoring, setting the stage for future enterprise opportunities. PLEASANTON, Calif.

MIT Selects Movano Health for Groundbreaking Study on Long COVID and Chronic Lyme Disease

Movano Inc. (NASDAQ:MOVE ) Q1 2024 Earnings Conference Call May 15, 2024 5:00 PM ET Company Participants John Mastrototaro - Chief Executive Officer Michael Soule - Vice President of Business Development Jeremy Cogan - Chief Financial Officer Stacy Salvi - Vice President of Products and Strategy Tyla Bucher - Chief Marketing Officer Michael Leabman - Founder and CTO Conference Call Participants Operator Greetings and welcome to the Movano Health Q1 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Movano Inc. (MOVE) Q1 2024 Earnings Call Transcript

Submits exemplary Sp02 clinical trial results as part of FDA 510(k) clearance process Plans launch of Evie Med and focuses on B2B opportunities Plans arterial blood pressure study for June Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. , May 15, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported first quarter 2024 results and provided a business update.

Movano Health Reports Q1 2024 Financial Results and Provides Business Update

Unlocking business-to-business opportunities with Evie Med, Movano Health's ring pulse oximeter, remains a key priority for the Company. PLEASANTON, Calif.

Movano Health Submits Exemplary Sp02 Clinical Trial Results in Key Step Towards FDA 510(k) Clearance Decision

Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., May 6, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report first quarter 2024 financial and operating results on Wednesday May 15, 2024, after the market close.

Movano Health to Report First Quarter 2024 Financial Results on Wednesday May 15, 2024

Movano Inc. (NASDAQ:MOVE ) Q4 2023 Results Conference Call April 4, 2024 5:00 PM ET Company Participants David Barnard - Senior Vice President of Investor Relations John Mastrototaro - CEO Michael Soule - VP of Business Development Jeremy Cogan - CFO & Secretary Michael Leabman - Founder, CTO & Director Tyla Bucher - Chief Marketing Officer Operator Greetings, and welcome to the Movano Health Fourth Quarter 2023 Earnings Call. [Operator Instructions].

Movano Inc. (MOVE) Q4 2023 Earnings Call Transcript

Financing included a strategic seed investment by a tier-1 multi-billion dollar medical device company and participation from insiders including members of Movano Health's management team and board of directors PLEASANTON, Calif. , April 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, has closed on a $24.1 million private placement, totaling 45.3 million units, with each unit consisting of one share of the Company's common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase a share of common stock, to a select group of investors that includes a tier-one multi-billion dollar medical device company, institutional and accredited investors, and members of the Company's management team and board of directors.

Movano Health Closes $24 Million Private Placement

Executes $24 million funding extending cash runway  Focuses on 2024 strategic pathway to FDA clearances driving B2B opportunities  Plans launch of Evie Med  Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. , April 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported fourth quarter and year end 2023 results and provided a business update.

News for Movano Stock (MOVE)